Vaxcyte, Inc. (PCVX) Stock Forecast
PCVX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.73 / 5 from 11 analysts
- Price target
- $117.30 average of analyst targets
- Upside to target
- +84.4% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-1.84
- 52-week range
- $40.32 – $73.82
PCVX analyst ratings
11 analystsNumber of analysts at each rating.
PCVX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PCVX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.11 | −$2.68 | −$1.67 | −$1.56 | −35.3% | 7 |
| Current fiscal year (2026) | −$8.16 | −$9.66 | −$6.19 | −$5.63 | −44.9% | 7 |
| Next fiscal year (2027) | −$7.07 | −$11.42 | −$4.96 | −$8.16 | +13.4% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PCVX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $87.1M | $0 | $620.0M | 0.0% | 9 |
PCVX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PCVX revenue: reported and forecast
PCVX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.16 | −$2.14 | −$2.14 | −$2.14 | −$2.11 | −2.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$8.48 | −$8.20 | −$8.20 | −$8.20 | −$8.16 | −3.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$7.42 | −$7.22 | −$7.22 | −$7.22 | −$7.07 | −4.8% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PCVX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PCVX beat in 2 of 12.
What analysts expect from PCVX
11 analysts cover Vaxcyte; their consensus rating is strong buy (4.73 on a 1–5 scale, where 5 is a strong buy). The average price target is $117.30, 84.4% above the latest close of $63.62. Analysts expect earnings of −$8.16 per share for 2026, −44.9% from a year earlier. For 2027 the average estimate is −$7.07 per share on revenue of $87.1 million. Vaxcyte beat the EPS estimate in 2 of the last 12 quarters.
Related: PCVX income statement, PCVX key metrics, PCVX chart. See the PCVX stock overview for the latest quote and news.
PCVX forecast FAQ
What is Vaxcyte's price target?
The average analyst price target for Vaxcyte is $117.30, 84.4% above the latest close of $63.62.
Is Vaxcyte a buy, hold or sell?
Of 11 analysts covering Vaxcyte, 9 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vaxcyte's EPS forecast?
Analysts forecast −$8.16 per share for 2026 (range −$9.66 to −$6.19); for 2027 the estimate is −$7.07.
When does Vaxcyte report earnings?
Vaxcyte is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $-1.84.
Does Vaxcyte usually beat earnings estimates?
Vaxcyte reported EPS at or above the analyst estimate in 2 of the last 12 quarters.